New therapeutic agents in veterinary dermatology.
The rapid development of therapeutic agents will continue to provide veterinarians with new options in treating dermatologic disease. However, we must not overlook the possibility of new applications for older drugs. Ideally, before a drug can be recommended for routine use, it should be evaluated for safety and efficacy using unbiased scientific methods. Unfortunately, this type of testing is expensive and may take years to complete. Veterinarians faced with managing a difficult skin disease may have to make decisions based on anecdotal information or case reports. The importance of good client communication cannot be overemphasized. The veterinarian must explain the benefits and risks of each therapeutic option. A written informed consent statement is advisable when using a drug in a manner not approved by the FDA.
Mundell
A C
AC
American College of Veterinary Dermatology, Seattle, Washington.
D042462:4-Quinolones; D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D002699:Chlorambucil / Q000627:therapeutic use; D002991:Clofazimine / Q000627:therapeutic use; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D017964:Itraconazole; D007559:Ivermectin / Q000627:therapeutic use; D007654:Ketoconazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D012871:Skin Diseases / Q000188:drug therapy / Q000662:veterinary*
D042462:4-Quinolones; D000890:Anti-Infective Agents; D002699:Chlorambucil; D017964:Itraconazole; D007559:Ivermectin; D002991:Clofazimine; D007654:Ketoconazole